logo

TBI

TrueBlue·NYSE
--
--(--)
--
--(--)
7.99 / 10
Outperform

Fundamental scrutiny indicates positive standing (8.0/10). Favorable drivers: Asset-liability ratio (%) and Equity multiplier, despite concerns regarding Total profit / EBIT (%) and ROE (diluted) (YoY growth rate %). Investment outlook: very promising.

Fundamental(7.99)SentimentTechnical

Analysis Checks(5/10)

Asset-liability ratio (%)
Value55.93
Score2/3
Weight2.69%
1M Return2.31%
Total operating revenue (YoY growth rate %)
Value1.39
Score0/3
Weight-1.87%
1M Return-1.96%
Equity multiplier
Value2.27
Score2/3
Weight3.56%
1M Return3.03%
ROE (diluted) (YoY growth rate %)
Value-0.40
Score0/3
Weight-1.80%
1M Return-1.90%
Equity ratio (Total liabilities / Shareholders’ equity attributable to parent company) (%)
Value1.27
Score2/3
Weight3.04%
1M Return2.63%
Total profit / EBIT (%)
Value88.16
Score1/3
Weight1.96%
1M Return1.76%
Current assets turnover ratio
Value4.06
Score1/3
Weight0.77%
1M Return0.75%
Operating revenue (YoY growth rate %)
Value1.39
Score0/3
Weight-2.02%
1M Return-2.13%
Total assets turnover ratio
Value1.75
Score2/3
Weight2.60%
1M Return2.36%
Current ratio
Value2.01
Score3/3
Weight91.06%
1M Return81.21%
Is TBI undervalued or overvalued?
  • TBI scores 7.99/10 on fundamentals and holds a Discounted valuation at present. Backed by its -5.30% ROE, -1.78% net margin, -4.79 P/E ratio, 0.53 P/B ratio, and 74.67% earnings growth, these metrics solidify its Outperform investment rating.